Download Files:
BRD3308
$110 – $720
Products Details
Product Description
– BRD3308 is a highly selective HDAC3 inhibitor with an IC50 of 54 nM. BRD3308 is 23-fold selectivity for HDAC3 over HDAC1 (IC50 of 1.26 μM) or HDAC2 (IC50 of 1.34 μM). BRD3308 suppresses pancreatic β-cell apoptosis induced by inflammatory cytokines or glucolipotoxic stress, and increases functional insulin release. BRD3308 activates HIV-1 transcription and disrupts HIV-1 latency[1][2][3].
Web ID
– HY-19618
Storage Temperature
– -20°C, 3 years; 4°C, 2 years (Powder)
Shipping
– Room Temperature
Applications
– COVID-19-anti-virus
Molecular Formula
– C15H14FN3O2
References
– [1]Barton KM, et al. Selective HDAC inhibition for the disruption of latent HIV-1 infection. PLoS One. 2014 Aug 19;9(8):e102684.|[2]Lundh M, et al. Histone deacetylase 3 inhibition improves glycaemia and insulin secretion in obese diabetic rats. Diabetes Obes Metab. 2015 Jul;17(7):703-7.|[3]Wagner FF, et al. An Isochemogenic Set of Inhibitors To Define the Therapeutic Potential of Histone Deacetylases in β-Cell Protection. ACS Chem Biol. 2016 Feb 19;11(2):363-74.
CAS Number
– 1550053-02-5
Molecular Weight
– 287.29
Compound Purity
– 98.07
SMILES
– O=C(C)NC1=CC=C(C(NC2=CC=C(F)C=C2N)=O)C=C1
Clinical Information
– No Development Reported
Research Area
– Infection; Metabolic Disease
Solubility
– DMSO : 250 mg/mL (ultrasonic)
Target
– Apoptosis;HDAC;HIV
Isoform
– HDAC1;HDAC2;HDAC3;HIV-1
Pathway
– Anti-infection;Apoptosis;Cell Cycle/DNA Damage;Epigenetics
Product type
– Reference compound
Disclaimer: All products are for research use only unless clearly stated otherwise on the product datasheet. Datasheets provided on the website are drafts for reference purpose only and you are requested to always refer to the hard copy included in the kit for your experimentation.
